Herndon Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Herndon Capital Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$20K	Hold	269	–	–	﹤0.01%	98
2017 Q1	$18K	Sell	269 -63	-19%	-$4.14K	﹤0.01%	101
2016 Q4	$21K	Buy	332 +21	+7%	+$1.32K	﹤0.01%	107
2016 Q3	$20K	Sell	311 -766	-71%	-$56.2K	﹤0.01%	141
2016 Q2	$80K	Sell	1,077 -390	-27%	-$28.9K	﹤0.01%	125
2016 Q1	$98K	Buy	1,467 +53	+4%	+$3.22K	﹤0.01%	131
2015 Q4	$96K	Buy	1,414 +1,073	+315%	+$66.2K	﹤0.01%	137
2015 Q3	$18K	Buy	341 +112	+49%	+$6.8K	﹤0.01%	152
2015 Q2	$14K	Buy	+229	New	+$12.5K	﹤0.01%	151

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Herndon Capital Management's LGND Position: Q2 2017 in Review

Herndon Capital Management held its Ligand Pharmaceuticals (LGND) position steady in Q2 2017 at 269 shares worth $20K. The position accounts for ﹤0.01% of the portfolio, ranked #98.

Herndon Capital Management first reported a position in LGND in Q2 2015 and has held it in 9 quarters since. The position peaked at $98K in Q1 2016. 265 funds tracked by Wall St. Rank hold LGND as of Q2 2017.

Herndon Capital Management held 269 shares of Ligand Pharmaceuticals worth $20K as of Q2 2017.
Herndon Capital Management left its Ligand Pharmaceuticals share count unchanged in Q2 2017.
Ligand Pharmaceuticals made up ﹤0.01% of Herndon Capital Management's portfolio in Q2 2017, its #98 holding.
Herndon Capital Management first reported a position in Ligand Pharmaceuticals in Q2 2015 and has held it in 9 quarters since.
Herndon Capital Management's Ligand Pharmaceuticals position peaked at $98K in Q1 2016.
265 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2017.

Based on Herndon Capital Management's 13F filing for Q2 2017, filed 4 Aug 2017.